Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,894 across all filing types
Latest filing 2020-04-24 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
独立董事对第七届董事会第14次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on various matters discussed at the 14th meeting of the 7th board of directors of a company. It includes detailed opinions on profit distribution plans, internal control evaluation reports, related party transactions, guarantees for subsidiaries, reappointment of accounting firms, accounting policy changes, employee stock ownership plans, and share repurchase plans. The content is focused on board-level decisions and approvals rather than a full financial report or earnings release. It is not a transcript, annual report, or audit report but rather a formal board/management information document reflecting governance and management decisions. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 3082 characters, which is consistent with a detailed board opinion document rather than a brief announcement or report publication notice.
2020-04-24 Chinese
关于收购子公司股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of a minority equity stake in a subsidiary company, Tianjin Tasly Pharmaceutical Marketing Group Co., Ltd., by the parent company Tasly Pharmaceutical Group Co., Ltd. It details the transaction amount, parties involved, related party nature, and the impact on the company. The document is a formal disclosure of a related party transaction and equity acquisition, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on the transaction specifics and compliance with regulatory requirements. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions of equity stakes in subsidiaries.
2020-04-24 Chinese
关于召开2019年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2019 Annual General Meeting (AGM) of TianShiLi Pharmaceutical Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items including the 2019 annual report and financial statements, and instructions for shareholders. The document is a formal announcement inviting shareholders to the AGM and providing procedural information, rather than the actual annual report or financial statements themselves. The document length is 3130 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2020-04-24 Chinese
为子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding guarantees provided by the parent company for the financing of its subsidiaries. It includes extensive information about the guarantee amounts, the subsidiaries involved, their business scope, financial data as of December 31, 2019, and the legal and procedural compliance of the guarantees. The document is not a financial report, earnings release, or management discussion but rather a formal disclosure about guarantees related to financing activities. It does not contain financial statements or management analysis but focuses on capital structure and financing guarantees. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (over 13,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice.
2020-04-24 Chinese
关于筹划重大资产出售的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding the progress of a major asset sale. It references previous announcements and states that the transaction is ongoing, with discussions and due diligence in progress. The document is relatively short (978 characters) and serves as a progress update rather than a full financial report or detailed filing. It does not contain financial statements or detailed analysis but is an update on a capital restructuring event. Therefore, it fits best under Capital/Financing Update (CAP).
2020-04-16 Chinese
关于养血清脑丸增加阿尔茨海默病（AD）适应症获得临床试验通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the approval of a clinical trial notification for a new indication of a drug. It details the clinical trial approval, drug development background, market situation, and potential impact on the company. It does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about a clinical trial approval and related information, not a financial report or earnings release. The document length is short (1766 characters), and it is an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS).
2020-03-31 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.